12 January 2023This recent study concludes that in patients with melanoma brain metastasis (MBM), the addition of radiotherapy resulted in a favorable overall survival (OS) on systemic therapy. In BRAF-mutated MBM patients, immune checkpoint blockade as first-line therapy and BRAF+MEK as second-line therapy were associated with a significantly prolonged OS.
12 January 2023According to this recent study, frailty appears to be unrelated to the occurrence of severe immune-related adverse events (irAEs), however, it is an indicator of irAE-related adverse sequelae, such as hospital admission.
12 January 2023According to this recent study, in patients with resected stage IIIB-C cutaneous melanoma, nivolumab improved recurrence-free survival (RFS) versus placebo and ipilimumab, and overall survival (OS) versus placebo after post-recurrence survival adjustment.
12 January 2023According to this recent study, health-related quality of life was stable with adjuvant pembrolizumab, with no clinically meaningful decline observed.The results - in conjunction with the improved RFS and manageable safety previously reported - support the use of adjuvant pembrolizumab for high-risk stage II melanoma.
12 January 2023This study discusses tumor-associated macrophages (TAMs) in melanoma, their interactions with checkpoint inhibitor antibodies and emerging monoclonal antibodies (mAbs) targeting different aspects of TAM biology and their potential to be translated to the clinic.
15 December 2022Authors of this clinical review describe the current literature related to the gut microbiome in the setting of immunotherapy, and provide an overview of interventions under investigation that may modulate the gut microbiome.
15 December 2022According to this recent study, MCUA controls melanoma aggressive behavior and therapeutic sensitivity. Manipulations of mitochondrial calcium and redox homeostasis, in combination with current therapies, should be considered in treating advanced melanoma.
15 December 2022The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma. The study concludes that nivolumab showed efficacy consistent with previous adjuvant studies in a population resembling current practice using American Joint Committee on Cancer eighth edition, reaffirming nivolumab as a standard of care for melanoma adjuvant treatment.
14 December 2022Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have improved the survival of people with metastatic melanoma. Authors of this recent study assessed the feasibility, acceptability, and utility of a novel model of nurse-led, telehealth-delivered survivorship care (MELCARE) for this survivor group.The study concludes that MELCARE was feasible and acceptable with high levels of utility.
14 December 2022The aim of this article is to review the relationship between melanoma and underserved communities as well as discuss the current explanations behind these observations.
